The Drug Controller General Of India (Dcgi) Has Approved Zydus Cadila’s New Drug Application (Nda) To Cater To Growing Demand From Chronic Liver Diseases Therapeutics Market
North America is projected to lead the global chronic liver disease therapeutics market due to the increasing focus of players on collaboration strategies to expand their business. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for the development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. The global chronic liver diseases therapeutics market is expected to witness significant growth owing to the growing prevalence of liver disease around the globe. According to the European Association for the Study of the Liver, the liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. Thus a high number of patients with liver disease such as cirrhosis is propelling the growth of the chronic liver diseases ther...